| # | Title | Journal | Year | Citations |
|---|
| 1 | Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies | Lancet HIV,the | 2017 | 805 |
| 2 | Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Lancet HIV,the | 2014 | 542 |
| 3 | Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 | Lancet HIV,the | 2016 | 461 |
| 4 | Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study | Lancet HIV,the | 2017 | 379 |
| 5 | COVID-19 in patients with HIV: clinical case series | Lancet HIV,the | 2020 | 350 |
| 6 | Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 | Lancet HIV,the | 2019 | 341 |
| 7 | HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform | Lancet HIV,the | 2021 | 340 |
| 8 | Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study | Lancet HIV,the | 2018 | 337 |
| 9 | Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study | Lancet HIV,the | 2017 | 333 |
| 10 | Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models | Lancet HIV,the | 2020 | 295 |
| 11 | Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial | Lancet HIV,the | 2015 | 285 |
| 12 | Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort | Lancet HIV,the | 2020 | 279 |
| 13 | Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study | Lancet HIV,the | 2018 | 273 |
| 14 | Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study | Lancet HIV,the | 2014 | 254 |
| 15 | Maintaining HIV care during the COVID-19 pandemic | Lancet HIV,the | 2020 | 250 |
| 16 | CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study | Lancet HIV,the | 2015 | 249 |
| 17 | Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population | Lancet HIV,the | 2014 | 245 |
| 18 | Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study | Lancet HIV,the | 2016 | 232 |
| 19 | Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis | Lancet HIV,the | 2015 | 227 |
| 20 | HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial | Lancet HIV,the | 2015 | 225 |
| 21 | Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study | Lancet HIV,the | 2017 | 220 |
| 22 | Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study | Lancet HIV,the | 2015 | 213 |
| 23 | The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis | Lancet HIV,the | 2021 | 199 |
| 24 | Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey | Lancet HIV,the | 2016 | 197 |
| 25 | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial | Lancet HIV,the | 2021 | 190 |
| 26 | Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial | Lancet HIV,the | 2015 | 188 |
| 27 | Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial | Lancet HIV,the | 2017 | 187 |
| 28 | Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis | Lancet HIV,the | 2017 | 187 |
| 29 | Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial | Lancet HIV,the | 2018 | 187 |
| 30 | Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis | Lancet HIV,the | 2017 | 183 |
| 31 | Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study | Lancet HIV,the | 2015 | 180 |
| 32 | Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis | Lancet HIV,the | 2016 | 180 |
| 33 | Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study | Lancet HIV,the | 2015 | 173 |
| 34 | The immediate effect of the Same-Sex Marriage Prohibition Act on stigma, discrimination, and engagement on HIV prevention and treatment services in men who have sex with men in Nigeria: analysis of prospective data from the TRUST cohort | Lancet HIV,the | 2015 | 172 |
| 35 | Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis | Lancet HIV,the | 2018 | 170 |
| 36 | Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study | Lancet HIV,the | 2016 | 168 |
| 37 | Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis | Lancet HIV,the | 2017 | 163 |
| 38 | Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial | Lancet HIV,the | 2016 | 159 |
| 39 | Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study | Lancet HIV,the | 2016 | 157 |
| 40 | Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study | Lancet HIV,the | 2018 | 155 |
| 41 | Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study | Lancet HIV,the | 2016 | 154 |
| 42 | Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis | Lancet HIV,the | 2016 | 151 |
| 43 | Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report | Lancet HIV,the | 2020 | 151 |
| 44 | Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis | Lancet HIV,the | 2018 | 147 |
| 45 | Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17 | Lancet HIV,the | 2018 | 145 |
| 46 | Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial | Lancet HIV,the | 2020 | 145 |
| 47 | U=U taking off in 2017 | Lancet HIV,the | 2017 | 144 |
| 48 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial | Lancet HIV,the | 2016 | 143 |
| 49 | Understanding the HIV disparities between black and white men who have sex with men in the USA using the HIV care continuum: a modelling study | Lancet HIV,the | 2014 | 139 |
| 50 | Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting | Lancet HIV,the | 2019 | 139 |
